Supplementary Table S1. Summary of clinical trials at the basis of the current international guidelines for the management of cancer-associated thrombosis.

Study	Number of patients	Anticoagulant used	Comparator	Primary outcomes		VTE events (%)	HR (95% IC) for recurrence of VTE	Major bleeding (%)	HR (95% IC) for major bleeding
Injectable anticoagulants versus VKA									
CLOT	676	Dalteparin	VKA	Recurrence of VTE		7 vs 15	0.48 (0.30–0.77)	6 vs 4	NA
Main-LITE	737	Tinzaparin	Usual care (UFH and VKA)	Effectiveness: Recurrence of VTE	Safety: All bleeding	4.9 vs 5.7 at 3 months	AD: -0.8 (-4.1-2.4)	13 vs 19.8	NA
Home-LITE	480	Tinzaparin	Usual care (tinzaparin plus VKA)	Recurrence of VTE		3.3	NA	No difference	NA
CANTHANOX	146	Enoxaparin	VKA	Combined outcome (recurrent VTE or major bleeding)		10.5 vs 21.1	RR: 2.02 (0.88-4.65)	7 vs 16	NA
ONCENOX	122	Enoxaparin (low and high dose)	VKA	Recurrence of VTE		6.3 (HD) vs 6.9 (LD) vs 10	NA	11.1 (HD) vs 6.5 (LD) vs 2.9	NA
RIETECAT	4451	Enoxaparin	Tinzaparin or dalterapin	Recurrence of VTE		2 vs 2.5	0.81 (0.48-1.38)	3.1 vs 1.9	1.4 (0.8-2.46)
CATCH	900	Tinzaparin	VKA	Effectiveness: Recurrence of VTE or death	Safety: All bleeding	6.9 vs 10	0.65 (0.41–1.03)	2.7 vs 2.4	0.89 (0.4-1.99)
DOACs versus LMWHs									
HOKUSAI-VTE CANCER	1050	Edoxaban	Dalteparin	Recurrence of VTE + major bleeding		7.9 vs 11.3	0.71 (0.48–1.06)	6.9 vs 4	1.77 (1.03–3.04)
SELECT-D	406	Rivaroxaban	Dalteparin	Recurrence of VTE		4 vs 11	0.43 (0.19–0.99)	6 vs 4	1.83 (0.68–4.96)
CASTA-DIVA	158	Rivaroxaban	Dalteparin	Major bleeding		6.4 vs 10.1	0.75 (0.21–2.66)	1.4 vs 3.7	0.36 (0.04–3.43)

Study	Number of patients	Anticoagulant used	Comparator	Primary outcomes		VTE events (%)	HR (95% IC) for recurrence of VTE	Major bleeding (%)	HR (95% IC) for major bleeding
ADAM-VTE	300	Apixaban	Dalteparin	Effectiveness: Recurrence of VTE	Safety: Major bleeding	0.7 vs 6.3	0.099 (0.013–0.780)	0 vs 1.4	Not computable
CARAVAGGIO	1170	Apixaban	Dalteparin	Effectiveness: Recurrence of VTE + worsening of vascular or venous obstruction.	Safety: Major bleeding	5.6 vs 7.9	0.63 (0.37–1.07)	3.8 vs 4	0.82 (0.40–1.69)
CANVAS	671	DOACs	LMWH	Effectiveness: Recurrence of VTE	Safety: Major bleeding	6.1 vs 8.8	Not reported	5.2 vs 5.6	Not reported

AD: absolute difference; DOAC: direct oral anticoagulant; HR: hazard ratio; IC: confidence interval; LMWH: low molecular weight heparin; RR: relative risk; VKA: vitamin K antagonists; vs: versus; VTE: venous thromboembolism.